PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro

PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro

BackgroundThe co-occurrence of pulmonary hypertension (PH) in patients with pulmonary fibrosis (PF) is linked to a more unfavorable prognosis and increased mortality compared to PF cases without PH. Early intervention and comprehensive management are pivotal for improving survival outcomes. Proprote...

ver descrição completa

Detalhes bibliográficos
Main Authors: Jiancheng Lin, Zetao Pan, Jiayan Sun, Xiaowan Wang, Di Yin, Cunyang Huo, Qiang Guo
Formato: Artigo
Idioma:English
Publicado em: Frontiers Media S.A. 2024-12-01
Colecção:Frontiers in Medicine
Assuntos:
pulmonary fibrosis
pulmonary hypertension
PCSK9
EMT
Wnt
β-catenin
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fmed.2024.1509168/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1509168/full

Registos relacionados